Dead Stock in Pharmacy Distribution: Identifying, Quantifying, and Eliminating It
In pharmaceutical distribution, dead stock doesn't just tie up capital — it creates compliance risk and write-off exposure. Here's a data-driven approach to identifying and clearing it.
Dead stock — inventory that has not moved within a defined period and is unlikely to move before it expires or becomes commercially obsolete — is a persistent challenge in pharmaceutical distribution. Unlike retail consumer goods, where unsold stock can typically be returned, discounted, or donated, pharmaceutical dead stock carries unique constraints: expiry dates that cannot be extended, regulatory requirements around disposal, and the reputational and financial risk of a stock write-off.
Quantifying the Problem
Most pharmaceutical distributors know they have a dead stock problem. Few have quantified it precisely. The typical approach — a periodic manual stocktake, followed by a review of lines that haven't moved recently — understates the problem significantly because it is retrospective and inconsistent.
A data-driven approach starts with a clear definition: a SKU is dead stock if it has had zero outbound movement in the last 90 days and its current stock level exceeds the expected demand for the period remaining before its nearest expiry date. Applying this definition continuously, across the full active SKU range, reveals the true scale of the problem — which in operations we have reviewed is typically 8–15% of total inventory value.
Root Causes
Dead stock in pharmaceutical distribution accumulates for predictable reasons. Minimum order quantities from manufacturers that exceed demand for slower-moving lines. Seasonal medications ordered at volumes appropriate for peak demand but not drawn down in the subsequent off-season. Product range decisions — expanding into a new therapy area, for example — where the demand never materialised at the projected level.
Understanding the root cause matters because it determines the remediation. Minimum order quantity dead stock is addressed through supplier negotiation or purchasing consolidation. Seasonal dead stock is addressed through demand-aligned ordering, not simply reducing order volumes.
The Role of Expiry Date Tracking
In pharmaceutical distribution, FEFO (First Expiry, First Out) stock rotation is not a best practice — it is a regulatory and commercial obligation. Yet in many warehouses operating without a WMS with expiry tracking, FEFO discipline depends entirely on the awareness and conscientiousness of individual pickers. The inevitable result is that near-expiry stock is bypassed in favour of newer receipts, and short-dated product approaches its expiry unnoticed.
ZifyWMS tracks expiry dates at the batch level for every pharmaceutical SKU, enforces FEFO picking automatically through its mobile app, and surfaces near-expiry alerts with configurable lead times — typically 90 days before expiry for slow-moving lines, giving the business time to take commercial action before the stock becomes a write-off.
Commercial Recovery Options
The earlier dead stock is identified, the more recovery options are available. At 90+ days before expiry, return-to-wholesaler arrangements may be viable. At 60 days, promotional pricing or transfer to a higher-demand branch can clear the line. Below 30 days, options narrow significantly. The economic value of early identification — enabled by continuous, automated dead stock monitoring — is therefore not just about avoiding write-offs: it is about preserving the range of recovery actions available to the business.
